Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glycosylated fibronectin as a biomarker for preeclampsia and preeclampsia-related complications

10 Dec 2024

Abstract excerpt

• What’s already known about this topic? • Glycosylated fibronectin (GlyFn) emerges as a biomarker for preeclampsia, particularly in early pregnancy (11–13 weeks). After 20 weeks of gestation, the predictive performance of GlyFn is similar to that of the sFlt-1/PlGF ratio. • What does this study add? • In women with suspected or confirmed preeclampsia after 20 weeks of gestation, GlyFn can be used as a biomarker...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Pregnancy and preeclampsia studies
Share to Preterm Birth and Chorioamnionitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39662167
DOI: 10.1016/j.preghy.2024.101177

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glycosylated fibronectin as a biomarker for preeclampsia and preeclampsia-related complicationsPMID 39662167Read ↗

Preeclampsia pathogenesis and prediction - where are we now: the focus on the role of galectins and miRNAsSemantic proximity Read ↗

Clinical tools and biomarkers to predict preeclampsiaSemantic proximity Read ↗

An updated view on the origin and use of angiogenic biomarkers for preeclampsiaSemantic proximity Read ↗

A Review of the Diagnosis, Risk Factors, and Role of Angiogenetic Factors in Hypertensive Disorders of PregnancySemantic proximity Read ↗

Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in PreeclampsiaSemantic proximity Read ↗

Maternal plasma proteome profiling of biomarkers and pathogenic mechanisms of early-onset and late-onset preeclampsiaSemantic proximity Read ↗

Maternal plasma proteome profiling of biomarkers and pathogenic mechanisms of early-onset and late-onset preeclampsiaSemantic proximity Read ↗

Unraveling preeclampsia: Is the fibrinogen‐to‐albumin ratio the key to early risk assessment?Semantic proximity Read ↗

Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsiaSemantic proximity Read ↗

Evaluation of albumin-based inflammatory markers as diagnostic tools in HELLP syndromeSemantic proximity Read ↗

Clinical utility of a glycosylated fibronectin test (Lumella TM ) for assessment of impending preeclampsiaSemantic proximity Read ↗

Biomarkers and the Prediction of Adverse Outcomes in PreeclampsiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.